Full-Time

VP – Clinical Development

Vant, Remote

Confirmed live in the last 24 hours

Roivant Sciences

Roivant Sciences

201-500 employees

Develops biopharmaceuticals and RNA therapeutics

Biotechnology
Healthcare

Senior

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Google Cloud Platform
Requirements
  • MD, DO, or non-US equivalent of MD degree with completion of residency in Internal Medicine or equivalent.
  • Minimum 5 years of experience at the Medical Director or Senior Medical Director level in early- to late-stage development in an industry (CRO and/or Pharma) setting.
  • Proven ability to: Plan and conduct clinical trials, Deliver high-quality results within established timelines, Demonstrated track record in working effectively in cross-functional teams and work streams (pharmacovigilance, biostatistics, clinical operations, and regulatory affairs).
  • Prior late phase clinical trial experience in autoimmune disorders is desirable.
  • Board certification in Rheumatology is desirable.
  • Ability to thrive in a fast-paced environment.
  • Proven ability to successfully manage multiple tasks and prioritize accordingly.
  • Attention to detail, internal drive to generate high-quality work, and sense of passion and urgency to achieve team and program goals.
  • Excellent analytical, problem-solving and strategic planning skills.
  • Strong interpersonal skills commensurate with the need to work closely with CROs, investigators, consultants, and team members across functions.
  • Exceptional written and oral communication skills to meet the needs of varied audiences.
  • Integrated understanding of FDA, EMA, ICH, and GCP guidelines. Prior interactions with FDA and EMA regulatory agencies is desirable.
Responsibilities
  • Provide clinical scientific leadership for the clinical study team.
  • Provide medical leadership for cross-functional internal workstreams including pharmacovigilance, biostatistics, clinical operations, regulatory affairs, etc.
  • Provide medical safety oversight of CRO medical monitors.
  • Collaborate with partners in the pharmacovigilance department in the analysis of clinical trial safety data.
  • Collaborate closely with partners in Clinical Operations, and be accountable for clinical trial conduct and timelines for associated key deliverables.
  • Lead the design and writing of clinical protocols and associated clinical documents.
  • Lead the writing of clinical and safety sections of key Program documents including Investigational New Drug submissions, Investigator Brochures, Clinical Study Reports, Development Safety Update Reports, Biologics License Applications, and other regulatory submissions and responses.
  • Be responsible for the preparation, analysis, and presentation of safety data to internal and external safety monitoring boards.
  • Assume primary responsibility for presentations related to clinical trial data and assist in the preparation of meeting abstracts, posters, and presentations related to clinical trial data.
  • Contribute to the writing of manuscripts and publications.
  • Comply with SOPs and adhere to ICH, GCP, and relevant regulatory guidelines.
  • Provide medical leadership for internal audits and regulatory inspections.
  • Assist in preparation of materials for Advisory Board meetings, BOD meetings, etc.
  • Develop and maintain strong, collaborative relationships with the broader organization.
  • Represent Roivant externally to trial site Investigators, KOLs, other stakeholders.

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates by maximizing the potential of these candidates through a combination of in-house development and strategic partnerships, which helps build a strong pipeline of drugs. One of its key subsidiaries, Genevant, specializes in RNA therapeutics, utilizing proprietary delivery platforms for mRNA, RNAi, and gene editing to create effective treatments for specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

Company Stage

IPO

Total Funding

$1.8B

Headquarters

New York City, New York

Founded

2014

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-11%
Simplify Jobs

Simplify's Take

What believers are saying

  • Roivant's recent $7.1B deal with Roche to acquire Telavant highlights its strong potential for lucrative partnerships and significant financial growth.
  • The company's diverse pipeline, including promising RNA therapeutics and gene editing technologies, offers substantial opportunities for breakthrough treatments.
  • Strategic investments, such as the $2.02 million from Exchange Traded Concepts LLC, indicate strong investor confidence and financial stability.

What critics are saying

  • The failure of the lupus drug brepocitinib in Phase 2 trials underscores the inherent risks in drug development and potential setbacks.
  • Rumors of acquiring Immunovant, Inc. could lead to financial strain and integration challenges if not managed properly.

What makes Roivant Sciences unique

  • Roivant Sciences leverages a unique business model that combines in-house product development with strategic partnerships, setting it apart from traditional biopharmaceutical companies.
  • The company's focus on RNA therapeutics and genetic disorders, particularly through its subsidiary Genevant, positions it at the forefront of cutting-edge medical treatments.
  • Roivant's ability to rapidly advance its drug pipeline and form strategic alliances allows it to bring innovative treatments to market more quickly and efficiently than many competitors.

Help us improve and share your feedback! Did you find this helpful?